Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
A user shared their positive experience with a 1900-graft FUE hair transplant by Dr. Ko at Newhair Clinic in Korea, costing $6,000. The user expressed satisfaction with the results and mentioned no longer experiencing stress over hair loss, but did not specify using any medications like finasteride.
Sulforaphane shows potential for hair regrowth, with users reporting reduced shedding and regrowth. Some users combine it with Minoxidil and finasteride for better results.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
The post discusses the rarity of baldness among South Korean men. Users suggest this could be due to early treatment, high beauty standards, accessibility of healthcare, and genetics. Treatments like finasteride and dutasteride are commonly used, and hair transplants are also popular.